New Hope for Immune Therapy for Children and Young Adults With Type 1 Diabetes: Founder of Orban Biotech's Landmark Findings for Abatacept Published in The Lancet
Links shared publicly online about this topic.
- 87total visits
New Hope for Immune Therapy for Children and Young Adults With Type 1 Diabetes: Founder of Orban Biotech's Landmark Findings for Abatacept Published in The Lancet
BROOKLINE, MA--(Marketwire - Aug 5, 2011) - Orban Biotech announced today that its C.E.O., Dr. Tihamer Orban, who was Principal Investigator for the Phase II clinical study run by TrialNet using Bristol Meyer's Abatacept for the treatment of Type 1 Diabetes Mellitus, presented the results of the trial at this...
View full resource at marketwire.com
Tags: Immune, Diabetes, Type 1 Diabetes, Rheumatoid Arthritis Medication, Biotech, Children's Health, Orencia
Most Recently Shared on August 8, 2011 at 12:58 pm By:
New Hope for Immune Therapy for People With T1DM: Landmark Findings for Abatacept Published in The Lancet: http://t.co/9ciZoGb
Advertisement
